Regeneron Pharmaceuticals, Inc.
REGN
$638.88
-$3.71-0.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.69% | 2.09% | -1.64% | 3.17% | 16.63% |
| Total Depreciation and Amortization | 8.94% | 12.59% | 11.84% | 12.56% | 13.80% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -246.23% | -520.31% | -66.75% | 35.26% | -133.15% |
| Change in Net Operating Assets | 147.30% | 186.14% | 174.21% | 65.55% | -980.76% |
| Cash from Operations | 26.80% | 12.63% | 19.39% | 16.53% | -16.58% |
| Capital Expenditure | -5.69% | -18.85% | -5.15% | -19.95% | -26.25% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -100.00% | -- |
| Cash Acquisitions | 80.00% | 80.00% | -64.77% | 80.80% | 69.95% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -212.36% | 115.89% | 117.48% | 111.41% | 118.28% |
| Cash from Investing | -1,177.53% | 74.51% | 82.71% | 76.12% | 97.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -12.49% | -56.60% | -86.67% | -74.09% | -37.14% |
| Repurchase of Common Stock | 6.20% | -9.31% | -27.06% | -41.05% | -46.34% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -299.04% | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 69.16% | 69.16% | -- | -- |
| Cash from Financing | -2.75% | -68.84% | -169.39% | -210.41% | -134.90% |
| Foreign Exchange rate Adjustments | -400.00% | 142.86% | -150.00% | 237.50% | 144.44% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -125.33% | 355.10% | 437.80% | 506.51% | 136.63% |